SENSEX NIFTY
YOU ARE HERE > MONEYCONTROL > MARKETS > PHARMACEUTICALS > News - Dr Reddys Laboratories
Dr Reddys Laboratories
BSE: 500124|NSE: DRREDDY|ISIN: INE089A01023|SECTOR: Pharmaceuticals
SET ALERT
|
ADD TO PORTFOLIO
|
WATCHLIST
LIVE
BSE
Sep 19, 17:00
3218.40
30.65 (0.96%)
VOLUME 27,895
LIVE
NSE
Sep 19, 17:00
3222.95
30.2 (0.95%)
VOLUME 310,686
News on Dr Reddys Laboratories
Select Year: 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2000-2005
Prefer pharma, Tata Steel, Ambuja Cements: Sanju Verma 

12.28 pm | 18 Sep 2014 |  Source: CNBC-TV18

Sanju Verma, CEO at Violet Arc Global Managers is of the view that one may prefer pharma stocks, Tata Steel from the metal space and Ambuja Cements fr...

Mkt optimism to continue; upbeat on IT: Prabhudas Lilladher 

12.00 pm | 18 Sep 2014 |  Source: CNBC-TV18

R Sreesankar, Head of Institutional Equities at Prabhudas Lilladher is extremely bullish on the Indian IT sector....

Top buzzing stocks to trade on September 17 

1.17 pm | 17 Sep 2014 |  Source: CNBC-TV18

Here are few top buzzing stocks picked by CNBC-TV18's analysts in trade today. We have NCC, Zee Entertainment, Hero MotoCorp, Bajaj Auto, IRB Infrastr...

DRL-GSK generic formulations deal under review: PharmAsia 

1.11 pm | 17 Sep 2014 |  Source: CNBC-TV18

The DRL-GSK deal was to sell branded generic formulations in emerging markets and was entered into in 2009....

See upside in Dr Reddy's Laboratories: Amit Gupta 

11.32 am | 17 Sep 2014 |  Source: CNBC-TV18

According to Amit Gupta of ICICIdirect, Dr Reddy's Laboratories should move up....

Buy Dr Reddy's Labs 3000 Call, sell 3100 Call: Subramanyam 

1.07 pm | 16 Sep 2014 |  Source: CNBC-TV18

Krish Subramanyam of Asit C.Mehta Investment Intermediates is of the view that one can buy Dr Reddy's Laboratories 3000 Call and sell 3100 Call....

Check out the trading strategies of Krish Subramanyam 

12.38 pm | 16 Sep 2014 |  Source: CNBC-TV18

Watch the interview of Krish Subramanyam of Asit C.Mehta Investment Intermediates with Ekta Batra and Anuj Singhal on CNBC-TV18, in which he shared hi...

Correction in offing; book profits: Ambareesh Baliga 

5.00 pm | 15 Sep 2014 |  Source: CNBC-TV18

"If we don’t have a correction you will not have investors coming in, in a big way especially the retail. Unless that happens you can’t have susta...

Mahantesh Sabarad overweight on pharma, prefers Dr Reddy's 

1.14 pm | 15 Sep 2014 |  Source: CNBC-TV18

Mahantesh Sabarad, Deputy Head of Research at SBI Capital Securities has a overweight stance on pharma space and prefers Dr Reddy's Laboratories....

Hope rally over: Why you should go back to 'boring sectors'

12.36 pm | 15 Sep 2014 |  Source: Moneycontrol.com

“The Street is building in a capex cycle of the likes in 2004 and 2008,” Elara says, adding, “while we do not dispute the recovery signals, we a...

Nifty unlikely to breach 8300; like Eicher Motors: SBI Cap 

12.01 pm | 15 Sep 2014 |  Source: CNBC-TV18

The house is also upbeat on Amrutanjan, where the management seems to be talking of huge upside in topline growth, says Mahantesh Sabarad, Deputy Head...

Halol contributes 35-40% to Sun's US sales: Angel Broking  

10.54 am | 11 Sep 2014 |  Source: CNBC-TV18

Nangra believes that most pharma stocks are trading at fair valuations post the recent run-up in the market. She likes Dr Reddys and IPCA Labs in the ...

US drug patent expiries to benefit Indian pharma industry

9.00 am | 11 Sep 2014 |  Source: PTI

Indian pharmaceutical companies have an opportunity to capitalise on the patent cliff and gain a greater share of the growing generics market....

Satish Ramanathan positive on pharma sector 

1.43 pm | 10 Sep 2014 |  Source: CNBC-TV18

Satish Ramanathan, Market Analyst has a positive view on the pharma sector....

Jyotivardhan Jaipuria neutral on pharma space 

1.29 pm | 10 Sep 2014 |  Source: CNBC-TV18

Jyotivardhan Jaipuria, Head of Research, BofA ML is neutral on pharma space....

Buy Dr Reddy’s Laboratories: Sudarshan Sukhani 

10.30 am | 08 Sep 2014 |  Source: CNBC-TV18

Sudarshan Sukhani of s2analytics.com is of the view that one may buy Dr Reddy’s Laboratories....

Nilesh Shah cautious on pharma sector 

5.15 pm | 01 Sep 2014 |  Source: CNBC-TV18

Nilesh Shah, MD & CEO of Envision Capital is cautious on the pharmaceutical sector....

See shared exclusivity on Copaxone generic 40mg: PLilladher 

11.38 am | 01 Sep 2014 |  Source: CNBC-TV18

According to Surajit Pal, both Natco Pharma and Dr. Reddy’s share exclusivity and two-three more companies are also expected to join the same....

Buy Dr Reddy's Laboratories, advises Sudarshan Sukhani 

11.21 am | 28 Aug 2014 |  Source: CNBC-TV18

Sudarshan Sukhani of s2analytics.com recommends buying Dr Reddy's Laboratories....

Buy Dr Reddy's Laboratories on declines: Amit Gupta 

11.47 am | 27 Aug 2014 |  Source: CNBC-TV18

Amit Gupta of ICICIdirect recommends buying Dr Reddy's Laboratories on declines and expects the stock to go beyond Rs 3000....

1 2 3
Quick Links for Dr Reddys Laboratories
Explore Moneycontrol
Stocks     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | Others
Mutual Funds     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.